WILL Summit Special Session: Six Venture Capital Leaders Envision the Future of Medicine

Fast-forward the clock ten years, and our medical landscape looks like this: The protracted struggle of “weight loss” has vanished from public discourse, as doctors wield molecular tools to edit genes, taming obesity, diabetes, and numerous other diseases. Occupational ailments will be a thing of the past, with researchers engineering proteins to prevent muscle strain. We will have bid farewell to influenza. Precision-guided cancer cell killers will eradicate tumors without sparing surrounding healthy tissue, freeing us from the fear of cancer...

These promising medical futures must be built upon today’s continuous technological innovations,Only technology has the power to fundamentally disrupt!

On July 9, 2016, as a special segment of the Legend Stars WILL Conference,XiangYiHui Season 2 MED TED Keynote EventHarnessing the Power of Regression Technology to Focus on the Imminent Future of Medicine. To this end, six leading investors have gathered at this event to jointly explore the technological forces reshaping healthcare entrepreneurship.

Mr. Lu Gang has served as the representative of Legend Holdings’ fund investors since 2004, responsible for evaluating, investing in, and managing multiple venture capital firms. He has conducted in-depth research on venture capital investment. From 2007 to 2009, he represented Legend Holdings in making direct investments in several companies specializing in health services, energy conservation and environmental protection, and chip design. After joining Legend Star, he led the establishment of Legend Star’s angel investment team and directly oversaw investment activities in sectors such as healthcare.

Mr. Ouyang has over 11 years of experience in venture capital and 16 years in the IT industry, with extensive expertise in corporate strategy, corporate governance, business operations, and venture capital. He has led or participated in numerous healthcare and medical projects, including Wuhan Asia Heart Biotechnology, Bonenghua Orthopedics, Rich Medical Devices, ET Xingtong, Berry Genomics, Ustar Diagnostics, Jenavalve, Kailian Medical, Kangda Medical, Zhuhai Dier, and Kalite.

Mr. Wang Hui is the Managing and Founding Partner of Honghui Capital Management, overseeing more than 30 transactions with a total value exceeding US$1 billion, including mergers and acquisitions, restructuring of listed companies, growth-stage investments, and early-stage investments. His key investment portfolio includes Kanghong Pharmaceutical, Poly Pharm, Angel Maternity Hospital, New Century Children’s Hospital, Kangning Hospital, New Vision Medical Technology, Yimeier Plastic Surgery Hospital, Jingyi Shares, and TriPath Imaging, Inc.

Morningside Venture Capital was founded in Boston in 1986 and entered the mainland China market in 1992. Currently, it focuses on investing in healthcare, life sciences, and related industries across North America, Europe, and mainland China. Its portfolio companies span various healthcare subsectors, including pharmaceutical R&D, diagnostic technologies, medical services, medical devices, and other healthcare-related fields. Since its inception, Morningside Venture Capital has remained committed to providing long-term venture capital to innovative startups and leveraging its global healthcare resources to offer strategic support to each portfolio company.

Mr. Tao Feng oversees minority equity investments in the healthcare sector for Fosun Pharma. He brings over a decade of experience in operations, management, and investment within the healthcare industry. He has achieved numerous notable and successful investments across pharmaceuticals, medical devices, healthcare services, and mobile health. Key investment deals he has led or participated in include Dian Diagnostics, Dirui Medical, Weigao Group, Shanhe Pharmaceutical Excipients, Chongqing Pharmaceutical Group, China-US United Imaging Healthcare, and Guahao.com, among others.

Mr. Xu Qian currently serves as a Partner and General Manager of Beijing Office at DT Capital Partners, with a primary focus on the healthcare sector and “Internet Plus.” He brings nearly 15 years of experience in the investment industry, having previously held positions at renowned institutions such as Fosun Pharma, CAS Holdings (Guoke Holdings), Legend Capital, and Tsinghua Xingye Investment. His investment portfolio includes projects such as WeDoctor Registration Network, Buchang Pharmaceuticals, and Mingyang Wind Power.

This event is free of charge. Entrepreneurs in the healthcare and medical sectors are warmly encouraged to apply. We will select 150 entrepreneurs to attend the on-site event, where they will have face-to-face discussions with prominent investors from Legend Star, Junlian Capital, Morningside Venture Capital, Honghui Capital, Fosun Pharma, and other leading firms.

Xiangyihui is a learning-oriented organization jointly established by VCBeat and Legend Star, designed to provide early-stage entrepreneurs in the healthcare industry with courses on strategic planning, team management, and business model construction, while also offering services such as financing facilitation and industry resource matchmaking.

Event Registration Link:http://m.grouplus.cn/ebsufm

Scan the QR Code to Enter Future Healthcare